UCB FY24 Documents Press release FY24 Earnings Call - Replay Title Format Download FY24 Earnings call - Transcript PDF Download Management Report - EN PDF Download Management Report - FR PDF Download Management Report - NL PDF Download Presentation - FY 2024 PDF Download Facts & Figures - FY 2024 PDF Download Integrated Annual Report PDF Download Excel Data XLS Download Integrated Annual Report ESEF Download HY24 documents Title Format Download Half-Year Report - EN PDF Download Half-Year Report - FR PDF Download Half-Year Report - NL PDF Download Other documents Title Format Download JP Morgan 2025 - Company Presentation PDF Download Reminder document for Full-Year 2024 modelling PDF Download Capital Market Call 30.09.2024 PDF Download Scientific Presentations, Abstracts, Posters, and Publications for Shareholders, Investors, and other Capital Market Participants Only The following documents are specifically for shareholders, investors, and other capital market participants. The webpages are not intended for members of the general public. Bimekizumab Rozanolixizumab Zilucoplan Corporate Governance Documents Also find more information on the dedicated section of our website. Governance charter Dealing code Code of conduct UCB Reports Archive ENGFRNL Title Year Format Download Integrated Annual Report 2023 PDF Download Integrated Annual Report 2023 ESEF Download Half-Year Report 2023 PDF Download Integrated Annual Report 2022 PDF Download Integrated Annual Report 2022 ESEF Download View more Contact UCB IR Team investor-relations@ucb.com or a specific team member:Antje Witte, Head of Investor RelationsTel: +32 2 559 9414E-mail: Antje.Witte@ucb.com Sahar Yazdian, Investor Relations Lead Tel: +32 2 559 9137E-mail: Sahar.Yazdian@ucb.com Book a virtual meeting Send us feedback UCB IR App